Biopharma News : Biopharma and Pharma news from all around the world :
- AOP Health on Rare Diseases: Information. Collaboration. Innovation.
- Almirall’s 2025 Results
- Virion Therapeutics Reports Broad and Sustained Anti-HBV Immunity Following a Single VRON-0200 Dose in the Majority of Chronically HBV-Infected Patients From its Phase 1b Study at CROI 2026
- Nuclera and leadXpro Partner to Accelerate Structure-Based Drug Design for Complex Membrane Proteins
- Sensorion Announces Leadership Changes
- Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position
- Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program
- VB Spine Announces Intent to Acquire Exclusive Rights to Augmedics’ Spine Platform
- Europe Oncology Genomics Tracker Captures Oncologist Perspectives Across Major European Markets – Data Report by DeciBio Consulting LLC
- Worldwide Clinical Trials Completes Acquisition of Catalyst Clinical Research
- Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
- New ECCO data show subcutaneous (SC) infliximab (Remsima™ SC) effectively recaptures and maintains disease control after drug holiday
- Genentech Announces Positive Phase III Results for Gazyva in Primary Membranous Nephropathy, Marking a Significant Milestone in This Autoimmune Disease
- Galderma Announces Appointment of New Chief Financial Officer
- Enpro Increases Quarterly Dividend
- Cencora Closes $3.0 Billion Senior Notes Offering
- Zeon Corporation Makes Strategic Investment in Chemify to Accelerate Digital Chemistry Innovation and Drive Development of New Materials Through State-of-the-Art Automated Molecular Design and Synthesis
- iProov Dynamic Liveness Is the First and Only Solution to Achieve CEN/TS 18099 High and Ingenium Level 4 for Injection Attack Detection
- We Are All Sculptra: First-of-its-Kind Galderma Initiative to Demonstrate How Everyone Can Benefit from Sculptra’s Regenerative Properties
- Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
- New Blood Test Helps GPs Manage Brain Scan Delays, Brings Field Forward
- Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™
- Bioscience Association Manitoba Announces 2026 Industry Celebration Winners
- THX Pharma and Biocodex Announce a Strategic Licensing Agreement in Batten, Gaucher and Niemann-Pick Type C Diseases
- Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform
- IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence
- U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
- The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study
- 4Moving Biotech Announces the Closing of a €12 Million Financing to Advance a First-in-Class DMOAD in Knee Osteoarthritis
- ZCG-Backed Unimed Acquires Regenboog Shipping Pharmacy
News about Biotech, Pharma, Biopharma, Medical Devices, Diagnostics, Digital Health
- Gerresheimer AG: BaFin announces expansion of audit of 2024 consolidated financial statements and initiation of audit of 2025 Half-Year Financial Report
- BIO-Europe Spring® 2026 Charts the Future of Life Sciences from Lisbon’s Shores
- Darwin AG Announces Preliminary Group Revenue for 2025 and Confirms Strategic Growth Trajectory
- BRAIN Biotech announces 3M 25/26 results and breakthrough at BioIncubator company SolasCure: Aurase Wound Gel showing strong clinical evidence of superior debridement and healing in chronic wounds
- Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program
- #FutureFresenius: REJUVENATE in action – Delivering accelerated performance for long-term value creation; 2025 yet another year of strong delivery
- Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth
- Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab)
- Fresenius Supervisory Board extends ahead of schedule CEO Michael Sen’s contract by five years — Christian Pawlu to join Management Board for Fresenius Helios effective July 1, 2026
- CF PharmTech (HKEX: 2652.HK) Announces NMPA Acceptance of IND Application for ICF004, a Potential First-in-Class Inhaled Dry Powder Candidate Targeting Unmet Needs in PF-ILD
- Promatix Biosciences Presents Positive Preclinical Data with First-in-Class PBS293 EGFR×EphA2 Cis-Bispecific ADC Demonstrating Enhanced Tumour Selectivity
- Galenica focuses Bichsel’s business on home care services
- Sandoz confirms European Commission approval for Ranluspec® (ranibizumab), further strengthening overall biosimilars leadership and position in ophthalmology
- DocMorris receives TÜV certification for temperature-controlled delivery of pharmaceuticals
- Siegfried delivers strong profitability and continued growth
- BioVersys and partners’ phase 2a tuberculosis trial results published in New England Journal of Medicine
- Straumann Group delivers strong 2025 performance with continued market share gains, innovation and strategic progress
- Sandoz receives US FDA approval to expand Enzeevu® (aflibercept-abzv) label for multiple retinal indications
- Immunic Announces Closing of Oversubscribed Private Placement Financing
- Bayer Aktiengesellschaft: Monsanto announces Roundup™ class settlement agreement to resolve current and future claims
- Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update
- African Leaders Call for Sustainable Malaria Financing as Progress Stalls and Funding Crisis Deepens
- Viromed Medical AG: Globally unique preclinical data base – Saarland validation as key step toward first physical lung application
- Eckert & Ziegler and UJF Significantly Increase Production Volume for Actinium-225
- Sartorius Stedim Biotech releases Universal Registration Document 2025
- Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company
- Changes to the Composition of the Lonza Board
- DocMorris and Infermedica simplify health: from symptoms to solutions with the AI health companion
- Carl Zeiss Meditec with Weak Start to FY 2025/26
- Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth
- Palvella Therapeutics Announces Pricing of Upsized Public Offering
- Considering MEDVi QUAD in 2026? Read This Before Enrolling in Any Compounded ED Telehealth Program
- Premier Health Reports 2026 First Quarter Results
- ACTG Announces Publication of STOMP Results in the New England Journal of Medicine
- LENSAR® Provides Update on Pending Acquisition by Alcon
- Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
- Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress
- PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
- PROCEPT BioRobotics Reports Fourth Quarter 2025 Financial Results and Updates 2026 Revenue Guidance
- Celcuity To Participate in Upcoming Investor Conferences
- Celcuity To Participate in Upcoming Investor Conferences
- MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results
- MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results
- Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR
- Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR
- Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026
- Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer
- Prime Medicine to Participate in Upcoming Investor Conferences
- BrainsWay to Report Fourth Quarter and Full Year 2025 Financial Results on March 11, 2026
- Grace Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
- Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes
- ITM to Announce Phase 3 COMPETE Trial Post-Hoc Subgroup Analysis in Pancreatic Neuroendocrine Tumors and Host Satellite Symposium at ENETS 2026
- Synklino announces publication in American Journal of Transplantation highlighting proof-of-concept for SYN002 in eliminating CMV in human kidneys
- Novonesis delivered strong organic sales growth of 7% in 2025
- Incentive programs for the Executive Leadership Team, the Senior Leadership Team and directors, and other employees
- Ethris Part of Consortium to Receive up to EUR 148 Million European Commission Contract to Advance Novel Pandemic Influenza Vaccine
- 35Pharma to be Acquired by GSK to Accelerate Development of HS235, a Potential Best-in-Class Investigational Medicine for Pulmonary Hypertension (PH)
- Bicara Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock and Pre-Funded Warrants
- Ivim Health GLP-1 Weight Loss Program: Individualized Dosing, Pricing, and What Consumers Should Know in 2026
- Pulmo Balance: Ingredients, Pricing, and What Consumers Should Know in 2026
Sources for this page of Biopharma News : biopharma-reporter.com and worldpharmanews and pharmatimes.com and drugs.com and fiercepharma.com and scripintelligence.com and PR Newswire and Business Wire. Please visit all this very interesting websites for more info.
Biopharma News – Pharma News